Integrating MDM2 Inhibition Into Myelofibrosis Management

Predicting Suboptimal Ruxolitinib Response in Myelofibrosis: Lessons To Be Learned from the POIESIS Trial

The Future of Myelofibrosis: Emerging Therapies and Combination Strategies to Watch

Identifying Early Loss of JAK Inhibitor Response in Myelofibrosis: Current and Emerging Predictors

The POIESIS trial is evaluating navtemadlin plus ruxolitinib in JAK inhibitor–naive patients with myelofibrosis with a suboptimal response to ruxolitinib.

Pankit Vachhani, MD, discusses the rationale for evaluating navtemadlin as an add-on to ruxolitinib in myelofibrosis after a suboptimal response to ruxolitinib alone.

John Mascarenhas, MD, discusses navtemadlin's mechanism of action and its potential to shift the myelofibrosis treatment landscape

John Mascarenhas, MD, discusses preclinical and clinical data showing symptom improvement and spleen responses with navtemadlin in myelofibrosis.